<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="743">
  <stage>Registered</stage>
  <submitdate>15/09/2005</submitdate>
  <approvaldate>11/11/2005</approvaldate>
  <actrnumber>ACTRN12605000726651</actrnumber>
  <trial_identification>
    <studytitle>Kinetic Defects in Lipoprotein Metabolism in Patients with Renal Failure</studytitle>
    <scientifictitle>Kinetic Defects in Lipoprotein Metabolism in Patients with Renal Failure</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Chronic renal disease</healthcondition>
    <healthcondition>Lipoprotein metabolism</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Nil.</interventions>
    <comparator />
    <control />
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1. ApoB and apoAI metabolism </outcome>
      <timepoint>Following recruitment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2. Insulin sensitivity.</outcome>
      <timepoint>Following recruitment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Non-diabetic CRF (GFR 40-60 ml/min) and 20 age, sex and weight matched healthy controls. </inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Type 1 or 2 Diabetes mellitus; Nephrotic Syndrome; Renal Replacement Therapy; BMI &gt; 35 kg/m2; On lipid-modifying therapy; Alcohol consumption &gt; 3 standard drinks / day; Liver disease; Primary dyslipidaemia (familial hypercholesterolaemia or familial combined hyperlipidaemia) or non-uraemia related secondary dyslipidaemia; Untreated thyroid disease; Significant psychiatric disorder; Cyclical hormone therapy in females.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Case control</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/03/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cardiovascular Lipid Research Grant Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Cardiovascular Lipid Research Grant Pfizer</fundingname>
      <fundingaddress>38-42 Wharf Road
West Ryde NSW 2114 Australia
PO Box 57, West Ryde NSW 2114</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Western Australia School of Medicine and Pharmacology</sponsorname>
      <sponsoraddress>Rear 50 Murray Street
Perth WA 6000</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Sharan Dogra</name>
      <address>University of Western Australia
Medical Research Foundation Building
Level 3
Rear 50 Murray St
Perth WA 6000</address>
      <phone>+61 8 92240232</phone>
      <fax />
      <email>sdogra@meddent.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Doris Chan</name>
      <address>Department of Nephrology
Royal Perth Hospital
Wellington Street Campus
Perth WA 6000</address>
      <phone>+61 8 92242244</phone>
      <fax />
      <email>doris.chan@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>